Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 29 May 2014 New trial record
- 24 May 2007
- 22 Sep 2006